<DOC>
	<DOCNO>NCT00750360</DOCNO>
	<brief_summary>The present study collect data safety reactogenicity vaccine local target population ( 600 subject ) per requirement Korean Food Drugs Administration ( KFDA ) .</brief_summary>
	<brief_title>Study Monitor Safety Reactogenicity Fluarixâ„¢ Korean Subjects Aged &gt; 6 Months Age .</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female &gt; 6 month age time first vaccination . Subjects investigator believe and/or parents/guardians comply requirement protocol enrol study . Free obvious health problem establish medical history clinical examination judge investigator enter study . If subject female , must nonchildbearing potential , , childbearing potential , must abstinent use adequate contraceptive precaution 30 day prior vaccination , negative pregnancy test must agree continue precaution two month vaccination . Clinical sign acute febrile illness time entry study . Any treatment immunosuppressive drug , include oral parenteral corticosteroid . History allergic disease reaction likely exacerbate component vaccine previous severe reaction influenza virus vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Korea</keyword>
	<keyword>FluarixTM</keyword>
</DOC>